Bank of America Corp DE Has $13.42 Million Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Bank of America Corp DE lessened its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 76.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 591,864 shares of the life sciences company's stock after selling 1,946,869 shares during the period. Bank of America Corp DE owned about 0.77% of Integra LifeSciences worth $13,423,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Arrowstreet Capital Limited Partnership increased its holdings in shares of Integra LifeSciences by 7.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after purchasing an additional 913 shares in the last quarter. Quadrant Capital Group LLC increased its stake in shares of Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares during the period. Sterling Capital Management LLC increased its stake in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after buying an additional 1,931 shares during the period. Covestor Ltd raised its position in shares of Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after acquiring an additional 2,071 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in shares of Integra LifeSciences by 5.3% during the fourth quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company's stock valued at $947,000 after acquiring an additional 2,111 shares during the period. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Trading Up 6.7%

Shares of IART stock traded up $0.82 on Tuesday, hitting $13.12. The stock had a trading volume of 1,098,368 shares, compared to its average volume of 1,043,575. The firm has a market cap of $1.02 billion, a P/E ratio of -145.76, a PEG ratio of 0.73 and a beta of 1.27. Integra LifeSciences Holdings Co. has a twelve month low of $11.60 and a twelve month high of $32.66. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a fifty day moving average price of $16.63 and a two-hundred day moving average price of $21.17.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same quarter last year, the company earned $0.55 earnings per share. The firm's revenue was up 3.7% compared to the same quarter last year. As a group, analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the subject of a number of research reports. JMP Securities lowered their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Wells Fargo & Company reduced their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Truist Financial cut their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Finally, JPMorgan Chase & Co. decreased their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.